A 77-year-old man with metformin-treated type 2 diabetes, high blood pressure, moderate renal insufficiency, stable angina, and a history of phlebitis stopped taking aspirin in preparation for palpebral surgery. A day after the surgery, he presented to the ER with two transient ischemic attacks (TIAs) affecting the left arm. The patient complained to the examining neurologist…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

These four patients are receiving chronic anticoagulation therapy. Read the descriptions of their cases and decide which, if any, of them you would switch to dabigatran. Case 1 A 69-year-old man with a history of hypertension and colon cancer was found to be in atrial fibrillation during a preoperative assessment for colon resection. Metoprolol was…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

In the randomized, double-blind CALISTO (Comparison of Arixtra in Lower Limb Superficial Vein Thrombosis with Placebo) trial, 3002 patients with acute, symptomatic superficial-vein thrombosis in the legs, but without DVT or symptomatic PE, received either fondaparinux (2.5 mg) or placebo for 45 days. The primary efficacy endpoint ─ a composite of all-cause death, symptomatic PE…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

FUTURA (Fondaparinux Trial With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes)/OASIS-8 is the first trial to compare low-dose unfractionated heparin with conventional heparin dosing in PCI patients receiving fondaparinux. Sanjit Jolly and colleagues randomized 2026 non-STEMI high-risk patients undergoing PCI within 72 hours to either low-dose unfractionated heparin or a standard dose of heparin…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.